SPS
TNXP icon

Susquehanna Portfolio Strategies’s Tonix Pharmaceuticals TNXP Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-41,454
Closed -$1M – 1129
2025
Q3 		$1M Hold
41,454
– – 0.02% 684
2025
Q2 		$1.49M Buy
+41,454
New +$1.09M 0.03% 430

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Susquehanna Portfolio Strategies's TNXP Position: Q4 2025 in Review

Susquehanna Portfolio Strategies sold out of Tonix Pharmaceuticals (TNXP) in Q4 2025, closing a stake of 41,454 shares — an estimated $1M sold.

Susquehanna Portfolio Strategies first reported a position in TNXP in Q2 2025 and held it in 2 quarters. The position peaked at $1.49M in Q2 2025. 70 funds tracked by Wall St. Rank hold TNXP as of Q4 2025.

  • Susquehanna Portfolio Strategies reported no remaining Tonix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 41,454 Tonix Pharmaceuticals shares in Q4 2025, an estimated $1M.
  • Susquehanna Portfolio Strategies first reported a position in Tonix Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Susquehanna Portfolio Strategies's Tonix Pharmaceuticals position peaked at $1.49M in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q4 2025.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.